Reduced malignant glioblastoma recurrence post-resection through the anti-CD47 antibody and Temozolomide co-embedded in-situ hydrogel system
Author:
Publisher
Elsevier BV
Subject
Pharmaceutical Science
Reference30 articles.
1. A randomized trial of bevacizumab for newly diagnosed glioblastoma;Gilbert;N. Engl. J. Med.,2014
2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N. Engl. J. Med.,2005
3. Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection;Zhang;Nat. Nanotechnol.,2021
4. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas;Harris;J. Clin. Neurosci.,2001
5. Long-lived self-renewing bone marrow-derived macrophages displace embryo-derived cells to inhabit adult serous cavities;Bain;Nat. Commun.,2016
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An injectable biomimetic hydrogel adapting brain tissue mechanical strength for postoperative treatment of glioblastoma without anti-tumor drugs participation;Journal of Controlled Release;2024-09
2. Phagocytosis Checkpoints in Glioblastoma: CD47 and Beyond;Current Issues in Molecular Biology;2024-07-23
3. Bioengineer mesenchymal stem cell for treatment of glioma by IL‐12 mediated microenvironment reprogramming and nCD47‐SLAMF7 mediated phagocytosis regulation of macrophages;Exploration;2024-06-25
4. Opportunities and challenges for anti-CD47 antibodies in hematological malignancies;Frontiers in Immunology;2024-02-23
5. The cross-talk between macrophages and tumor cells as a target for cancer treatment;Frontiers in Oncology;2023-11-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3